Published in Women's Health Weekly, March 27th, 2003
The trial, conducted in the United States and Canada, is a double-blind placebo-controlled study of 161 patients.
The objective of the phase II/III clinical trial is to define the lowest effective dose of Bio-E-Gel to reduce the severity and frequency of moderate- to-severe hot flushes in menopausal women. In 2001, BioSante completed two phase I/II Bio-E-Gel clinical trials which profiled the blood levels of estradiol delivered by two different...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.